Since our establishment in 2003, CDCO staff have actively contributed to more than 120 publications, including a number of high impact journals.
The following is a small selection of key publications:
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C., et al (2004) Identification of an Antimalarial Synthetic Trioxolane Drug Development Candidate. Nature 430, 900-904.
Highly cited paper describing the discovery of the first synthetic peroxide antimalarial drug candidate to be tested in humans; drug is registered in India (Synriam™).
Charman, S. A., Arbe-Barnes, S., Bathurst, I. C., Brun, R., Campbell, M., et al (2011) Synthetic Ozonide Drug Candidate Oz439 Offers New Hope for a Single-Dose Cure of Uncomplicated Malaria. Proc. Natl. Acad. Sci. U. S. A. 108, 4400-4405.
Highly cited paper describing the discovery of the next generation synthetic ozonide candidate OZ439 with superior antimalarial efficacy and pharmacokinetics; currently in Phase II clinical trials.
Yuthavong, Y., Tarnchompoo, B., Vilaivan, T., Chitnumsub, P., S., Charman, S. A., et al (2012) Malarial Dihydrofolate Reductase as a Paradigm for Drug Development against a Resistance-Compromised Target. Proc. Natl. Acad. Sci. U. S. A. 109, 16823-16828.
Describing the structure-guided discovery of a plasmodial DHFR inhibitor effective against a resistance compromised target for the treatment of malaria.
Nilsen, A., LaCrue, A. N., White, K. L., Forquer, I. P., Cross, R. M., et al (2013) Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Sci. Transl. Med. 5, 177ra137.
Describing the discovery of a quinolone antimalarial active against blood and liver stages of malaria, thereby having the potential to contribute to malaria eradication.
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, et al. (2008) Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Abeta. Neuron 59, 43-55.
Highly cited paper describing the biology of a new class of compounds to treat Alzheimer's disease; the drug candidate is currently in Phase II trials.
Coteron, J. M., Marco, M., Esquivias, J., Deng, X., White, K. L., et al. (2011) Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium Falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential. J. Med. Chem. 54, 5540-5561.
Describing the discovery of a new antimalarial drug candidate active against a novel target; the candidate is currently undergoing Phase I clinical trials.
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., et al (2013) Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacol. Rev. 65, 315-499.
Highly cited paper representing the most comprehensive review to date on the topic of poorly water soluble drugs and formulation approaches for oral administration.
The majority of CDCO collaborations are protected by commercial-in-confidence agreements, which often limit or delay publication.